TriLink BioTechnologies, a Maravai LifeSciences company, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. This agreement will integrate TriLink's CleanCap mRNA capping technology into Quantoom's Ntensify (sa)mRNA production platform.
The collaboration aims to accelerate the RNA production process and enhance the accessibility of life-saving therapeutics and vaccines globally. CleanCap technology is recognized for producing optimal 5' cap structures with over 95% efficiency, which significantly improves mRNA yield and process time compared to legacy methods.
This partnership expands the reach of TriLink's proprietary capping technology into Quantoom's platform, which is known for its performance and ease-of-use in RNA production. The agreement supports customers in developing unique (sa)mRNA drugs through clinical development phases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.